Summary
The product Turinabol, manufactured by DuncanPharma.eu, was independently tested to verify its authenticity and potency. The sample, identified by batch number JF6148, was submitted by the reseller DuncanPharma.eu and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis confirmed the presence of Turinabol, with a measured concentration of 8.36 mg.
The testing process began on 15 May 2024, with the sample received on 23 May 2024, and analysis completed on 24 May 2024. While the results confirm the presence of the active ingredient, reseller-submitted samples should be critically evaluated, as they may represent selective batches. Independent third-party testing remains essential to ensure consistency across the market. This report is provided as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: DuncanPharma.eu
- Product Name: Turinabol
- Active Ingredient: Turinabol
- Batch Number: JF6148
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #42632
- Testing Ordered: 15 May 2024
- Sample Received: 23 May 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Optitropin.EU (Reseller)
- Analysis Paid For By: Optitropin.EU
Testing Results
- Specification: 10 mg
- Measured Concentration: 8.36 mg
- Accuracy: 83.60% (16.40% below the typical label claim)
- Variance: -16.40%
Verification Details
- Verification URL: https://janoshik.com/tests/42632_JPT3KKVLZIEA
Evaluation of Reseller-Submitted Testing
This analysis confirms the presence of Turinabol but warrants careful evaluation due to its submission and funding by the reseller DuncanPharma.eu. Resellers often select optimal batches for testing, which may not fully represent the quality of all available products. While Janoshik Analytical is known for its transparency and rigorous testing, independent validation across multiple batches remains necessary to ensure consistent product quality.
Conclusion
The analysis verifies that Turinabol is present in the sample, with a measured concentration of 8.36 mg. This result provides insight into the product’s composition but highlights the need for additional testing to confirm consistent dosing across different batches. This report is intended as an educational tool to support harm reduction and informed decision-making.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside independent third-party results. Readers are encouraged to use this information responsibly.
